HRP20160353T1 - Derivati 1,2,4-tiazolidin-3-ona i njihova uporaba u liječenju raka - Google Patents
Derivati 1,2,4-tiazolidin-3-ona i njihova uporaba u liječenju raka Download PDFInfo
- Publication number
- HRP20160353T1 HRP20160353T1 HRP20160353TT HRP20160353T HRP20160353T1 HR P20160353 T1 HRP20160353 T1 HR P20160353T1 HR P20160353T T HRP20160353T T HR P20160353TT HR P20160353 T HRP20160353 T HR P20160353T HR P20160353 T1 HRP20160353 T1 HR P20160353T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- thiadiazol
- oxo
- pharmaceutically acceptable
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21373509P | 2009-07-08 | 2009-07-08 | |
| PCT/GB2010/001315 WO2011004162A2 (en) | 2009-07-08 | 2010-07-08 | Compounds useful as medicaments |
| EP10759940.9A EP2451794B1 (en) | 2009-07-08 | 2010-07-08 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160353T1 true HRP20160353T1 (hr) | 2016-05-06 |
Family
ID=43086401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160353TT HRP20160353T1 (hr) | 2009-07-08 | 2010-07-08 | Derivati 1,2,4-tiazolidin-3-ona i njihova uporaba u liječenju raka |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9162994B2 (enExample) |
| EP (1) | EP2451794B1 (enExample) |
| JP (1) | JP5982281B2 (enExample) |
| KR (1) | KR101765957B1 (enExample) |
| CN (1) | CN102596923B (enExample) |
| AU (1) | AU2010270030B2 (enExample) |
| BR (1) | BR112012000370B1 (enExample) |
| CA (1) | CA2767291C (enExample) |
| DK (1) | DK2451794T3 (enExample) |
| EA (1) | EA026674B1 (enExample) |
| ES (1) | ES2567753T3 (enExample) |
| HR (1) | HRP20160353T1 (enExample) |
| HU (1) | HUE027263T2 (enExample) |
| IL (1) | IL216723A (enExample) |
| ME (1) | ME02443B (enExample) |
| MX (1) | MX337516B (enExample) |
| NZ (1) | NZ597075A (enExample) |
| PL (1) | PL2451794T3 (enExample) |
| RS (1) | RS54718B1 (enExample) |
| SG (1) | SG177558A1 (enExample) |
| SI (1) | SI2451794T1 (enExample) |
| SM (1) | SMT201600225B (enExample) |
| WO (1) | WO2011004162A2 (enExample) |
| ZA (1) | ZA201108901B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100931145B1 (ko) * | 2008-07-04 | 2009-12-10 | 현대자동차주식회사 | 조정식 킥 다운 스위치의 조작기구 |
| WO2013108026A1 (en) | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| CN114539273A (zh) | 2016-06-07 | 2022-05-27 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| CU24560B1 (es) | 2017-01-23 | 2021-12-08 | Cadent Therapeutics Inc | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio |
| HRP20241239T1 (hr) | 2017-03-23 | 2024-12-06 | Jacobio Pharmaceuticals Co., Ltd. | Novi heterociklički derivati korisni kao shp2 inhibitori |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| AU2019366312B2 (en) | 2018-10-22 | 2025-04-24 | Novartis Ag | Crystalline forms of potassium channel modulators |
| WO2020095010A1 (en) | 2018-11-05 | 2020-05-14 | Balticgruppen Bio Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| CN109879808B (zh) * | 2019-03-05 | 2020-10-16 | 北京工业大学 | 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途 |
| GB201910093D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| GB201910092D0 (en) | 2019-07-15 | 2019-08-28 | Balticgruppen Bio Ab | New formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB202015585D0 (en) * | 2020-10-01 | 2020-11-18 | Betagenon Bio Ab | New compounds |
| GB202100352D0 (en) | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
| GB202112529D0 (en) | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| WO2025017193A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods of treating cardiomyopathy induced by metabolic inflexibility |
| WO2025017194A1 (en) | 2023-07-20 | 2025-01-23 | Betagenon Ab | Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler |
| WO2025027205A1 (en) | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093624A (en) | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| HUP0302002A3 (en) | 2000-05-11 | 2007-02-28 | Consejo Superior Investigacion | Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them |
| WO2006045581A1 (en) | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
| KR20080034436A (ko) | 2005-07-21 | 2008-04-21 | 베타게논 에이비 | 암 치료에 사용되는 티아졸 유도체 및 유사체 |
| WO2008090356A1 (en) | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
-
2010
- 2010-07-08 WO PCT/GB2010/001315 patent/WO2011004162A2/en not_active Ceased
- 2010-07-08 KR KR1020117030830A patent/KR101765957B1/ko active Active
- 2010-07-08 ES ES10759940.9T patent/ES2567753T3/es active Active
- 2010-07-08 HR HRP20160353TT patent/HRP20160353T1/hr unknown
- 2010-07-08 JP JP2012519055A patent/JP5982281B2/ja active Active
- 2010-07-08 EP EP10759940.9A patent/EP2451794B1/en active Active
- 2010-07-08 MX MX2012000441A patent/MX337516B/es active IP Right Grant
- 2010-07-08 DK DK10759940.9T patent/DK2451794T3/en active
- 2010-07-08 HU HUE10759940A patent/HUE027263T2/en unknown
- 2010-07-08 ME MEP-2016-66A patent/ME02443B/me unknown
- 2010-07-08 RS RS20160255A patent/RS54718B1/sr unknown
- 2010-07-08 CA CA2767291A patent/CA2767291C/en active Active
- 2010-07-08 NZ NZ597075A patent/NZ597075A/xx unknown
- 2010-07-08 SG SG2012001236A patent/SG177558A1/en unknown
- 2010-07-08 CN CN201080030894.9A patent/CN102596923B/zh active Active
- 2010-07-08 EA EA201200102A patent/EA026674B1/ru not_active IP Right Cessation
- 2010-07-08 PL PL10759940T patent/PL2451794T3/pl unknown
- 2010-07-08 BR BR112012000370-4A patent/BR112012000370B1/pt active IP Right Grant
- 2010-07-08 US US13/381,426 patent/US9162994B2/en active Active
- 2010-07-08 AU AU2010270030A patent/AU2010270030B2/en active Active
- 2010-07-08 SI SI201031157A patent/SI2451794T1/sl unknown
-
2011
- 2011-12-01 IL IL216723A patent/IL216723A/en active IP Right Grant
- 2011-12-05 ZA ZA2011/08901A patent/ZA201108901B/en unknown
-
2015
- 2015-10-14 US US14/883,190 patent/US9675596B2/en active Active
-
2016
- 2016-07-12 SM SM201600225T patent/SMT201600225B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160353T1 (hr) | Derivati 1,2,4-tiazolidin-3-ona i njihova uporaba u liječenju raka | |
| JP2012532854A5 (enExample) | ||
| EP0733033B1 (en) | Pharmaceutically active substituted aromatic compounds | |
| JP5180099B2 (ja) | 置換イミダゾール誘導体、組成物ならびにｐｔｐアーゼ阻害剤としての使用方法 | |
| AU2005210163B2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| DK171468B1 (da) | Pyrrol-, pyrazol- eller triazolforbindelser, farmaceutiske præparater indeholdende disse forbindelser samt deres anvendelse til fremstilling af antihypertensive midler og midler til behandling af kongestivt hjertesvigt | |
| JP3298641B2 (ja) | イミダゾール誘導体およびそのサイトカイン阻害剤としての使用 | |
| KR100776119B1 (ko) | 트리아졸 유도체 | |
| JP2008540574A5 (enExample) | ||
| JP2019052178A (ja) | ブロモドメイン阻害剤としての新規の置換された二環式化合物 | |
| JP2005510476A (ja) | 抗炎症剤として有用なスピロ−ヒダントイン化合物 | |
| US20100311748A1 (en) | Heterocyclic amides useful for the treatment of cancer and psoriasis | |
| HRP20170019T1 (hr) | Novi pirol-inhibitori od reduktaze s-nitrozoglutationa kao terapeutska sredstva | |
| AU2005270132A1 (en) | Anti-inflammatory medicaments | |
| US6878734B2 (en) | Gastrin and cholecystokinin receptor ligands(II) | |
| AU2005325676A1 (en) | Anti-inflammatory medicaments | |
| SK27299A3 (en) | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
| SK174699A3 (en) | Inhibitors of factor xa with a neutral p1 specificity group | |
| CN102395567A (zh) | 在治疗糖尿病和肥胖症中用作的tgr5激动剂的三唑和咪唑衍生物 | |
| CZ20022072A3 (cs) | Nepeptidylové inhibitory VLA-4 dependentní buněčné vazby použitelné pro léčbu zánětlivých, autoimunitních a respiračních onemocnění | |
| SK20052000A3 (sk) | Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb | |
| JPH10195063A (ja) | エチニルチアゾール誘導体 | |
| JPS61189282A (ja) | 駆虫剤としての５‐（アゾリルオキシフエニルカルバモイル）バルビツル酸誘導体及びその製法並びに該化合物を含有する駆虫用組成物 | |
| WO2021049628A1 (ja) | Ｐ２ｘ４受容体拮抗剤 | |
| EP1175406A1 (en) | Imidazoline derivatives as alpha-1a adrenoceptor ligands |